XML 66 R28.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenues Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2018
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2018 |  | 2017
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis: |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 728.9 |  |  | $ | 258.0 |  |  | $ | 986.9 |  |  | $ | 751.1 |  |  | $ | 207.1 |  |  | $ | 958.2 |
Interferon* | 371.4 |  |  | 178.9 |  |  | 550.3 |  |  | 464.8 |  |  | 183.5 |  |  | 648.3 |
TYSABRI | 249.7 |  |  | 212.4 |  |  | 462.1 |  |  | 305.5 |  |  | 239.5 |  |  | 545.0 |
FAMPYRA | — |  |  | 24.4 |  |  | 24.4 |  |  | — |  |  | 20.5 |  |  | 20.5 |
ZINBRYTA | — |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 10.7 |  |  | 10.7 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 188.0 |  |  | 175.9 |  |  | 363.9 |  |  | 46.4 |  |  | 1.0 |  |  | 47.4 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | — |  |  | — |  |  | — |  |  | 42.2 |  |  | 6.2 |  |  | 48.4 |
ALPROLIX | — |  |  | — |  |  | — |  |  | 21.0 |  |  | 5.0 |  |  | 26.0 |
Other Product Revenues: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 7.0 |  |  | 7.0 |  |  | — |  |  | 9.7 |  |  | 9.7 |
BENEPALI | — |  |  | 120.9 |  |  | 120.9 |  |  | — |  |  | 65.3 |  |  | 65.3 |
FLIXABI | — |  |  | 6.6 |  |  | 6.6 |  |  | — |  |  | 0.6 |  |  | 0.6 |
Total product revenues | $ | 1,538.0 |  |  | $ | 985.5 |  |  | $ | 2,523.5 |  |  | $ | 1,631.0 |  |  | $ | 749.1 |  |  | $ | 2,380.1 |
*Interferon includes AVONEX and PLEGRIDY
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2017 | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year | 159.4 |  |  | 641.2 |  |  | 5.8 |  |  | 806.4 |
Adjustments relating to prior years | 1.2 |  |  | 2.0 |  |  | 0.3 |  |  | 3.5 |
Payments/credits relating to sales in current year | (71.7 | ) |  | (227.7 | ) |  | (0.3 | ) |  | (299.7 | )
Payments/credits relating to sales in prior years | (77.4 | ) |  | (326.4 | ) |  | (8.7 | ) |  | (412.5 | )
Balance, as of March 31, 2018 | $ | 121.1 |  |  | $ | 695.1 |  |  | $ | 43.1 |  |  | $ | 859.3 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of March 31, 2018 |  | As of December 31, 2017
Reduction of accounts receivable | $ | 201.8 |  |  | $ | 189.6 |
Component of accrued expenses and other | 657.5 |  |  | 572.0 |
Total reserves | $ | 859.3 |  |  | $ | 761.6 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2018 |  | 2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | $ | 349.6 |  |  | $ | 323.5 |
Other revenues from anti-CD20 therapeutic programs | 93.6 |  |  | 17.1 |
Total revenues from anti-CD20 therapeutic programs | $ | 443.2 |  |  | $ | 340.6 |
Other revenues | Other revenues are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2018 |  | 2017
Revenues from collaborative and other relationships: |  |  |
AbbVie | $ | (4.7 | ) |  | $ | (5.9 | )
Samsung Bioepis and other | 17.9 |  |  | 12.2 |
Other royalty and corporate revenues: |  |  |
Royalty | 10.6 |  |  | 25.5 |
Other corporate | 140.6 |  |  | 58.2 |
Total other revenues | $ | 164.4 |  |  | $ | 90.0 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration